GB2111384A - Improvement in preventative and curative medicine - Google Patents
Improvement in preventative and curative medicine Download PDFInfo
- Publication number
- GB2111384A GB2111384A GB08123639A GB8123639A GB2111384A GB 2111384 A GB2111384 A GB 2111384A GB 08123639 A GB08123639 A GB 08123639A GB 8123639 A GB8123639 A GB 8123639A GB 2111384 A GB2111384 A GB 2111384A
- Authority
- GB
- United Kingdom
- Prior art keywords
- citrus
- acid
- blood
- lemon
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title description 2
- 230000006872 improvement Effects 0.000 title description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Natural products CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims abstract description 33
- 150000001875 compounds Chemical class 0.000 claims abstract description 31
- 210000004369 blood Anatomy 0.000 claims abstract description 24
- 239000008280 blood Substances 0.000 claims abstract description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 16
- 229940087305 limonene Drugs 0.000 claims abstract description 16
- 235000001510 limonene Nutrition 0.000 claims abstract description 15
- 241000196324 Embryophyta Species 0.000 claims abstract description 14
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 claims abstract description 11
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 claims abstract description 11
- 241001093501 Rutaceae Species 0.000 claims abstract description 7
- 230000023266 generation of precursor metabolites and energy Effects 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 7
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims abstract description 6
- 241000219926 Myrtaceae Species 0.000 claims abstract description 6
- 241000219050 Polygonaceae Species 0.000 claims abstract description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 6
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 6
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 6
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 6
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 6
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims abstract description 6
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims abstract description 6
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000005493 rutin Nutrition 0.000 claims abstract description 6
- 229960004555 rutoside Drugs 0.000 claims abstract description 6
- 239000000686 essence Substances 0.000 claims abstract description 5
- 241000207834 Oleaceae Species 0.000 claims abstract description 4
- 241000220151 Saxifragaceae Species 0.000 claims abstract description 4
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 230000007102 metabolic function Effects 0.000 claims abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 claims abstract description 4
- 239000000341 volatile oil Substances 0.000 claims abstract description 4
- 244000248349 Citrus limon Species 0.000 claims description 26
- 244000089742 Citrus aurantifolia Species 0.000 claims description 20
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims description 20
- 235000005979 Citrus limon Nutrition 0.000 claims description 20
- 150000003505 terpenes Chemical class 0.000 claims description 18
- 235000007586 terpenes Nutrition 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 230000028327 secretion Effects 0.000 claims description 12
- 240000004307 Citrus medica Species 0.000 claims description 11
- 241000207199 Citrus Species 0.000 claims description 10
- 235000011941 Tilia x europaea Nutrition 0.000 claims description 10
- 239000003995 emulsifying agent Substances 0.000 claims description 10
- 239000004571 lime Substances 0.000 claims description 10
- 208000016192 Demyelinating disease Diseases 0.000 claims description 9
- 206010012305 Demyelination Diseases 0.000 claims description 9
- 210000000170 cell membrane Anatomy 0.000 claims description 9
- 210000004185 liver Anatomy 0.000 claims description 9
- 238000012423 maintenance Methods 0.000 claims description 9
- 230000002503 metabolic effect Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 claims description 8
- 235000020971 citrus fruits Nutrition 0.000 claims description 8
- 235000016838 Pomo dAdamo Nutrition 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 7
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 claims description 6
- 208000010444 Acidosis Diseases 0.000 claims description 6
- 241001672694 Citrus reticulata Species 0.000 claims description 6
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 claims description 6
- 206010027417 Metabolic acidosis Diseases 0.000 claims description 6
- 206010027423 Metabolic alkalosis Diseases 0.000 claims description 6
- 102000015728 Mucins Human genes 0.000 claims description 6
- 108010063954 Mucins Proteins 0.000 claims description 6
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 6
- 241000468081 Citrus bergamia Species 0.000 claims description 5
- 235000001938 Citrus medica Nutrition 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 230000000202 analgesic effect Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 240000000560 Citrus x paradisi Species 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 240000008620 Fagopyrum esculentum Species 0.000 claims description 4
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 4
- 235000011613 Pinus brutia Nutrition 0.000 claims description 4
- 241000018646 Pinus brutia Species 0.000 claims description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 4
- 241001521328 Ruta Species 0.000 claims description 4
- 235000003976 Ruta Nutrition 0.000 claims description 4
- 244000064154 Ruta montana Species 0.000 claims description 4
- 235000007118 Ruta montana Nutrition 0.000 claims description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 4
- 230000001387 anti-histamine Effects 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000000739 antihistaminic agent Substances 0.000 claims description 4
- 150000001746 carotenes Chemical class 0.000 claims description 4
- 235000005473 carotenes Nutrition 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 239000003248 enzyme activator Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 229930003658 monoterpene Natural products 0.000 claims description 4
- 150000002773 monoterpene derivatives Chemical class 0.000 claims description 4
- 235000002577 monoterpenes Nutrition 0.000 claims description 4
- 210000004877 mucosa Anatomy 0.000 claims description 4
- 235000005806 ruta Nutrition 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 101800004538 Bradykinin Proteins 0.000 claims description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 3
- 101800001982 Cholecystokinin Proteins 0.000 claims description 3
- 208000017667 Chronic Disease Diseases 0.000 claims description 3
- 206010011224 Cough Diseases 0.000 claims description 3
- GVVPGTZRZFNKDS-YFHOEESVSA-N Geranyl diphosphate Natural products CC(C)=CCC\C(C)=C/COP(O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-YFHOEESVSA-N 0.000 claims description 3
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 3
- 102100035792 Kininogen-1 Human genes 0.000 claims description 3
- 102000006386 Myelin Proteins Human genes 0.000 claims description 3
- 108010083674 Myelin Proteins Proteins 0.000 claims description 3
- 208000003826 Respiratory Acidosis Diseases 0.000 claims description 3
- 206010038664 Respiratory alkalosis Diseases 0.000 claims description 3
- 241000208292 Solanaceae Species 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 230000002340 alkalosis Effects 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 230000000794 anti-serotonin Effects 0.000 claims description 3
- 239000003420 antiserotonin agent Substances 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 230000000740 bleeding effect Effects 0.000 claims description 3
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 230000005779 cell damage Effects 0.000 claims description 3
- 230000003915 cell function Effects 0.000 claims description 3
- 208000037887 cell injury Diseases 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 230000001882 diuretic effect Effects 0.000 claims description 3
- 230000002183 duodenal effect Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 239000003172 expectorant agent Substances 0.000 claims description 3
- 230000003419 expectorant effect Effects 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 230000013632 homeostatic process Effects 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- -1 monoterpene derivative geranyl-pyrophosphate Chemical class 0.000 claims description 3
- 210000005012 myelin Anatomy 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 3
- 230000003019 stabilising effect Effects 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 229910021654 trace metal Inorganic materials 0.000 claims description 3
- 239000011573 trace mineral Substances 0.000 claims description 3
- 235000013619 trace mineral Nutrition 0.000 claims description 3
- 230000036269 ulceration Effects 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 244000058084 Aegle marmelos Species 0.000 claims description 2
- 235000003930 Aegle marmelos Nutrition 0.000 claims description 2
- 240000000712 Casimiroa edulis Species 0.000 claims description 2
- 235000003936 Casimiroa edulis Nutrition 0.000 claims description 2
- 241000030995 Cephalotaxus sinensis Species 0.000 claims description 2
- 244000276331 Citrus maxima Species 0.000 claims description 2
- 244000080335 Citrus x limonia Species 0.000 claims description 2
- 244000295848 Citrus x nobilis Species 0.000 claims description 2
- CAHGCLMLTWQZNJ-WZLOIPHISA-N Euphol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@@]2(C)[C@H]([C@@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-WZLOIPHISA-N 0.000 claims description 2
- QFPQAPVPUNXXDR-UHFFFAOYSA-N Euphol Natural products CC(=CCCCC1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3)C QFPQAPVPUNXXDR-UHFFFAOYSA-N 0.000 claims description 2
- 244000148716 Feronia limonia Species 0.000 claims description 2
- 235000008756 Feronia limonia Nutrition 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 claims description 2
- 241000288906 Primates Species 0.000 claims description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 2
- 241001078984 Zanthoxylum americanum Species 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 125000002723 alicyclic group Chemical group 0.000 claims description 2
- 150000008064 anhydrides Chemical group 0.000 claims description 2
- 229940095714 cider vinegar Drugs 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 230000001632 homeopathic effect Effects 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 230000028709 inflammatory response Effects 0.000 claims description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 2
- 125000000686 lactone group Chemical group 0.000 claims description 2
- 235000020778 linoleic acid Nutrition 0.000 claims description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- 229960001285 quercetin Drugs 0.000 claims description 2
- 235000005875 quercetin Nutrition 0.000 claims description 2
- 239000003270 steroid hormone Substances 0.000 claims description 2
- 150000003431 steroids Chemical group 0.000 claims description 2
- 150000003648 triterpenes Chemical class 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 1
- 244000061354 Manilkara achras Species 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 claims 1
- 231100001078 no known side-effect Toxicity 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract description 6
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 abstract description 6
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 abstract description 2
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 abstract description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 2
- 229930003268 Vitamin C Natural products 0.000 abstract description 2
- 229940093797 bioflavonoids Drugs 0.000 abstract description 2
- 108010084210 citrin Proteins 0.000 abstract description 2
- 239000011782 vitamin Substances 0.000 abstract description 2
- 229940088594 vitamin Drugs 0.000 abstract description 2
- 229930003231 vitamin Natural products 0.000 abstract description 2
- 235000013343 vitamin Nutrition 0.000 abstract description 2
- 235000019154 vitamin C Nutrition 0.000 abstract description 2
- 239000011718 vitamin C Substances 0.000 abstract description 2
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 2
- VXUGVISSBXKUEL-UHFFFAOYSA-N 2-hydroxypropanoic acid;2-oxopropanoic acid Chemical compound CC(O)C(O)=O.CC(=O)C(O)=O VXUGVISSBXKUEL-UHFFFAOYSA-N 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 abstract 1
- 206010067125 Liver injury Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 231100000234 hepatic damage Toxicity 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000008818 liver damage Effects 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 244000182210 Calocarpum sapota Species 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- WOJQWDNWUNSRTA-MSGMIQHVSA-N limonoic acid Chemical compound C=1([C@H](O)[C@@]2(CC[C@H]3[C@@]([C@@]22[C@H](O2)C(O)=O)(C)C(=O)C[C@@H]2[C@]3(CO)[C@H](CC(O)=O)OC2(C)C)C)C=COC=1 WOJQWDNWUNSRTA-MSGMIQHVSA-N 0.000 description 1
- GZFKAVWTLKZZPF-CVZATPLPSA-N limonoic acid Natural products CC1(C)O[C@H]2CC(=O)OC[C@]23[C@H]4CC[C@@]5(C)[C@@H](OC(=O)[C@H]6O[C@@]56[C@]4(C)CC(=O)[C@@H]13)c7cocc7 GZFKAVWTLKZZPF-CVZATPLPSA-N 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This invention deals with a homoepathic type compound. The compound consists in whole or in part (dependant on the batch) of- Limonene, Limonin, Rutin, and Pinene, all of which are natural, i.e. bio- organic substances found in different higher plants of the botanical families (i) Rutaceae, Myrtaceae and Coniferae, also in Polygonaceae, Solanceae, Oleaceae, Saxifragaceae, eg. All contain volatile oils (volatile essences), it also consists of ascorbic acid (vitamin C), linoleic acid, linolenic acid (vitamin F), isopropyl alcohol bioflavonoids (vitamin P group, citrin). The compound was found to have useful (ii) pharmacological properties in the treatment of Post irradiation disease, complications following chemotherapy, Biliary/liver damage, Lipoproteinaemias, Arteriosclerosis, Decompensated Diabetes with Ketoacidosis. Acts as cofactor in Intermediary Metabolism of nutrients (and Acetylcoenzye A), Lowers Pyruvate-Lactate in Blood, and generally aids the healing process (iii) of the body by restoring the pH of body fluid and correcting impaired metabolic function. i
Description
SPECIFICATION
Improvement in preventative and curative medicine
This invention deals with a homoeopathic compound hereinafter to be known as
Metamorf (Compound 561). The compound in this invention consists in whole or in part (dependent on the batch) of-Limonene, Limonin,
Rutin and Pinene, all of which are natural, i.e. bioorganic substances found in different higher plants of the botanical families Rutaceae,
Myrtaceae and Coniferae, also in Polygonaceae,
Solanaceae, Oleaceae, Saxifragaceae, etc. All of these contain volatile oils (volatile essences) in their ieaves, blossoms, fruits, peels, needles and barks; it also consists of ascorbic acid (vitamin C), linoleic acid, linolenic acid (vitamin F), isopropyl alcohol, bioflavonoids (vitamin P group, citrin).
Botany
The main species of the family Rutaceae are the genus Citrus with the following species: Citrus auratium amara L. (orange), Citrus auran tifolia vijapura Christm., Citrus acida Christm. (lime),
Citrus medica L; (acid lime), Citrus bergamia L.
(Risso, lemon) C. grandis L. (grape fruit), C.
decumana (Osbeck grapefruit), C. Lemon L.
(lemon) C. medica var. limonum L. (lemon limonero); C. limonia L. (lemon); C. medica matulunga L. (citron), C. nobilis Lour, C. reticulata
Blando (mandarin orange), C. sinesis L. (orange),
Feronia limonia L. Phyllodendron amurense Rupr.,
Ruta agrestis graveolens L. Ruta montana Mill.,
Zanthoxylum americanum Mill., hermaphroditum schinifolium, Aegle marmelos L., Casimiroa edulis
L., C. sapota, and others belonging to the families
Myrtaceae L. and Coniferae L.
Bio-organic chemistry
The volatile essences or volatile oils of
Limonene, Limonin, Rutin and Pinene consist of mixtures of unsaturated alicyclic (ring) compounds called terpenes (or terpenoids) which have the empirical formula (C5H8)n and oxidation products of these. These terpenes are built up of isoprene (C5H8) units. These terpenes are used in other industries. The monoterpene Limonene
C10H16, is synthetized by the citrus plant as d
Form, I-Form, and dl (racemic inactive) form or dipentene. It is a liquid of a pleasant lemon like odour, and of the structure formula
which reads as 1-methyl-4-(1-methylethelnyl)-cyclohexene.
The Pinene, also a monoterpene C,OH18, is naturally synthetized by the pine tree as d-a- pinene or l-a-pinene. It is a liquid of characteristic pine needle scent of turpentine. Its structure formula is
which reads as 2,6,6-trimethyl-bycyclo 3.1.1hept-2-ene.
The Rutin (or Quercetin), a penta-hydroxyflavone-rutinoside C27H300,6, as hydroscopic anhydride forms needle crystals of pale yellow to brown colour. It is synthetized in the nature of many plants especially in buckwheat (Fagopyrum esculentum Moench, Polygonaceae). Its structure formula is
Limonin or Limonoic acid, a triterpene of the
Euphol type of the empirical formula C26H3008, is the bitter principle of lemons and other Rutaceae.
It consists of two lactone rings, a p-substituted flavouring, a ketonic oxygen atom and two ethereal oxygen rings. Its bitter crystals dissolved in isopropanolol. Its structure formula
which resembles the steroid structure, produced by plants whereas steroid hormones are produced by primates and man.
Pharmacology
The terpenes Limonene and Limonic are important ingredients in the food industry. A compound (Metamorf-compound 561) based on a mixture of these two substances has been found to have useful pharmacological properties.
The British Pharmacopoea 1 968 accepts lemon peel as an expectorant, diuretic, antihistamine and anti-inflammatory agent. The Liquor ammoniae citricus is one of the oldest remedies used in cough mixtures.
The Metamorph Compound 561 acts as a buffer within the alkaline reserve of blood. It helps to stabilise the optimal pH of the blood by maintaining the acid/bas balance of the physiologic Buffer systems of blood. It shifts the metabolic or respiratory acidosis by assisting to decompose the lactic acid; or, the metabolic or respiratory alkalosis by stabilising the Na:K ratio in blood and in the cells in vivo.
It maintains the cell membrane by assisting the
Na-pump and calcium ions, which penetrate the cell membrane, act as emulsifiers and maintain the surface activity. It acts as an inorganic trace element carrier for the intracellular enzymes containing Zn or Cu ions, and act so as enzyme activators by carrying the co-enzyme, i.e. the trace metal as catalyst. It influences the maintenance of the Zn:Cu:Cd, of the Ca:Mg, and
Na:K by preserving their optimal biological ratio.
Terpenes are manufactured by the human liver where they are needed for the production of mevalonic acid. This acid is an intermediate affecting the intermediary metabolism of acetate and acetyl-CoA degradation. Limonene obviously mediates the condensation of the liver's own monoterpene derivative geranyl-pyrophosphate and acts as an intermediator of its "head to tail" addition.
The optimal pH of blood in chronic respiratory and metabolic acidosis and alkalosis is particularly important for the maintenance of the homeostasis of the fluidity: coagulability of the circulating blood, the interstitial tissue fluids, and of the total internal environment as defined by
Bernard and Cannon. This is of particular importance in the various chronic diseases and diseases of metabolic origin.
In homoepathic doses it acts as a stimulator of gastric and duodenal secretion of mucin and affects beneficially ulcerations of these segments of the gastro intestinal tract, and aspirin induced stomach bleeding. It increases pancreatic enzyme secretion, and secretion of Pancreozymin, all of which have anti-inflammatory characteristics. It also acts as anitihistamine, antiserotonin, and anti-bradykin and so affects its analgesic action.
The auto-immunization process of the central nervous system results in demyelination when the lymphocytes fail to recognise the body's own proteins, and giest myelin, the compound initiates here an inflammatory response. The compound mediates the reversibility of the early demyelination and improves or slows down the process in later stages of the multiple sclerosis patient.
Treatment also aids in the restoration of a proper cell function, following cell damage by improving the metabolic function. In this way the sick cell can be converted into a normal one.
Summary
Metamorf (Compound 561) was found to be acting as:
(i) A buffer and stabilizer within the alkaline reserve of blood.
(ii) Influences the majority of enzymatic processes at the cellular and subcellular level, dependent on an optimal pH.
(iii) It has a saponin-like action in the sense of an emulsifier acting on the cell membrane, one of which is the maintenance of the fluidity: coagulability of blood.
(iv) It is a detoxificating agent mediating a correct performance of the intermediary metabolism of the liver, particulary that of the mevalonic acid.
(v) It mediates the secretion of mucin by its local action on the mucosa of the upper part of the gastro-intestinal tract.
(vi) Bradykinin triggers off the pain. The compound neutralizes this and/or influences its intensity, and shows it analgesic properties.
(vii) Mediates the reversibility of the early demyelination and improves or slows down the process in later stages of the multiple sclerosis.
Claims (Filed on 24 Aug 1982)
1. A homeopathic type compound comprising entirely of terpenes in emulsions. All natural extracts of higher plants of the botanic families.
Ruteceae. Myrtaceae. Coniferae. Polygonaceae.
Solanaceae Oleaceae. Saxifragaceae..etc. with no chemical additives. or All natural higher plant extracts Limonene. Limonin. Pinene. Ascorbic
Acid. Natural Pure Cider Vinegar. Carotene. Ethel
Alcohol. Linolleic Acid. Linolenic Acid. Vehicle.
Emulsifier. Citrus Acida Christmas (lime). Citrus
Bergamia L. (Risso Lemon) Citrus Lemon L.
(Lemon), or all natural higher plants extracts
Limonene. Limonin. Pinene. Ascorbic Acid.
Carotene. Ethel Alcohol. Linoleic Acid. Linolenic
Acid. Vehicle. Emulsifier. Citrus Acida'Christmas (Lime). Citrus Begamia L. (Risso Lemon). Citrus
Lemon L. (Lemon). Citrus Medica Matulunga L.
(Citron). Citrus Reticulata Blando. Ruta Agrestis
Graveolens L., Ruta Montana Mill., and all other
Higher Plants dependent on the batch. These terpenes are built up of Isoprene (CsH8) units.
2. A homeopathice type compound as claimed in claim 1. The main species of the family Rutaceae are the genus Citrus with the following species:
Citrus auratium amara L. (Orange) Citrus auran tifolia vijapura Christm. Citrus acida Christm.
(Lime). Citrus medica L. (Acid Lime). Citrus bergamia L. (Risso, lemon). Grandis L.
(Grapefruit). C. decumana (Osbeck grapefruit), C.
Lemon L. (lemon) C. medica var. limonum L.
(lemon limonero) C. limonia L. (lemon); C. medica
**WARNING** end of DESC field may overlap start of CLMS **.
Claims (6)
1. A homeopathic type compound comprising entirely of terpenes in emulsions. All natural extracts of higher plants of the botanic families.
Ruteceae. Myrtaceae. Coniferae. Polygonaceae.
Solanaceae Oleaceae. Saxifragaceae..etc. with no chemical additives. or All natural higher plant extracts Limonene. Limonin. Pinene. Ascorbic
Acid. Natural Pure Cider Vinegar. Carotene. Ethel
Alcohol. Linolleic Acid. Linolenic Acid. Vehicle.
Emulsifier. Citrus Acida Christmas (lime). Citrus
Bergamia L. (Risso Lemon) Citrus Lemon L.
(Lemon), or all natural higher plants extracts
Limonene. Limonin. Pinene. Ascorbic Acid.
Carotene. Ethel Alcohol. Linoleic Acid. Linolenic
Acid. Vehicle. Emulsifier. Citrus Acida'Christmas (Lime). Citrus Begamia L. (Risso Lemon). Citrus
Lemon L. (Lemon). Citrus Medica Matulunga L.
(Citron). Citrus Reticulata Blando. Ruta Agrestis
Graveolens L., Ruta Montana Mill., and all other
Higher Plants dependent on the batch. These terpenes are built up of Isoprene (CsH8) units.
2. A homeopathice type compound as claimed in claim 1. The main species of the family Rutaceae are the genus Citrus with the following species:
Citrus auratium amara L. (Orange) Citrus auran tifolia vijapura Christm. Citrus acida Christm.
(Lime). Citrus medica L. (Acid Lime). Citrus bergamia L. (Risso, lemon). Grandis L.
(Grapefruit). C. decumana (Osbeck grapefruit), C.
Lemon L. (lemon) C. medica var. limonum L.
(lemon limonero) C. limonia L. (lemon); C. medica
matulunga L. (citron), C. nobilis Lour; C. reticulata
Blando (mandarin orange). C. sinesis L. (orange);
Feronia limonia L. Phyllodendron amurense
Rupre., Ruta agrestis gravelens L. Ruta montana
Mill., Zanthoxylum americanum Mill., hermaphoditum schinifolium, Aegle marmelos L.,
Casimiroa edulis L., sapota, and others belonging to the families Myrtaceae L. and Coniferae L.
3. As claimed in any preceding claim. The volatile essences or volatile oils of Limonene,
Limonin, Rutin and Pinene consist of mixtures of unsaturated alicyclic (ring) compounds called terpenes (or terpenoids) which have the empirical formula (C5H8)n and oxidation products of these.
These terpenes are built up of isoprene (C5H8) units. These terpenes are used in other industries.
The monoterpene Limonene (C,OH,6) is synthetized by the citrus plant as d-Form, I-Form, and dl (racemic inactive) form or dipentene. It is a liquid of a pleasant lemon like odour, and of the structure formula which reads as 1-methyl-4- (methyl-ethelnyl)-cyclohexene. The Pinene, also a monoterpene C,OH,6 is naturally synthetized by the pine tree as d-a-pinene or l-a-pinene. It is a liquid of characteristic pine needle scent of terpentine. and of a structure formula which reads as 2,6,6,-trimethylbycyclo 3.1.1 .-hept-2-ene. The
Rutin (or Quercetin), a penta-hydroxy-flavonerutinoside C27 H30 O,, as hygroscopic anhydride forms needle crystals of pale yellow to brown colour.It is syntheetized in the nature of many plants especially in buckwheat (Fagopyrum esculentum Moench, Polygonaceae. Limonin or limonic acid a triterpene of the Euphol type of the empirical formula C26 H30 8 is the bitter principle of lemons and other Rutaceae. It consists of two lactone rings, a jB-sunstituted flavouring, a ketonic oxygen atom and two ethereal oxygen rings. Its bitter crystals dissolved in isopropanolol., and of a structured formula which reads, resembles the steroid structure, produced by plants whereas steroid hormones are produced by primates and man.
4. As claimed in any preceding claim. The terpenes Limonene and Limonin are important ingredients. A compound (Metamorf compound 561. "2" (561) "3" (561) based on a mixture of these two substances has been found to have useful pharmacological properties. The British
Pharmacopoea 1 968 accepts lemon peel as an expectorant, diuretic, anti-histamine, and anti inflammatory agent. The Liquor ammoniae citricus is one of the oldest remedies used in cough mixtures. Terpenes are manufactured by the human liver where they are needed for the production of mevalonic acid. This acid is an intermediate affecting the intermediary metabolism of acetate and acetyl-CoA degradation. Limonene mediates the condensation of the liver's own monoterpene derivative geranyl-pyrophosphate, and acts as an intermediator of its "head to tail" addition.It helps to stabalise the optimal pH of the blood by maintaining the acid/bas balance of the physiologic Buffer systems of blood. It shifts the metabolic or respiratory acidosis by assisting to decompose the lactic acid; or, the metabolic or respiratory alkalosis by stabilising the Na:K ratio in blood and in the cells in vivo. It maintains the cell membrane by assisting the Na-pump and calcium ions which penetrate the cell membrane, acts as emulsifiers and maintain the surface activity. It acts as an inorganic trace element carrier for the intracellular enzymes containing Zn or Cu ions, and act so as enzyme activators by carrying the co-enzyme, i.e. the trace metal as catalyst. It influences the maintenance of the
Zn:Cu:Cd: of the Ca:Mg, and Na:K by preserving their optimal biological ratio.
5. As claimed in any preceding claim. The optimal pH of blood in chronic respiratory and metabolic acidosis and alkalosis is particularly important for the maintenance of the homeostasis of the fluidity: coagulability of the circulating blood, the interstitial tissue fluids, and of the total internal environment as defined by
Bernard and Cannon. This is of particular importance in the various chronic diseases, and diseases of metabolic origin. In homoepathic type doses, the compounds acts as stimulators of gastric and duodenal secretion of mucin, and affects beneficially ulceration of these segments of the gastro intestinal tract, it does not irritate the mucosa of the gastro intestinal tract, and asprin induced stomach bleeding is also benefically affected. It increases pancreatic enzye secretion of Pancreozymin, all of which have antiinflammatory characteristics.It also acts as antihistamine, antiserotonin, and anti-bradykin and so affects its anagesic action. The autoimmunization process of the central nervous system results in demyelination when the lymphocytes fail to recognise the body's own proteins, and digest myelin, the compounds initiates here an anti inflammatory response. The compounds mediate the reversibility of the early demyelination and improves or slows down the process in later stages of multiple sclerosis patients. Treatment also aids in the restoration of a proper cell function, following cell damage by improving the metabolic function. In this way the sick cell can be converted into a normal one. The penetration of the oxygen into the damaged tissue is made possible. The effectiveness of the volatile essences. It aids the regeneration of the affected cartilage tissue by contributing to the synthsis of the glycoaminoglycans, and so
improving the permeability of the cartilage, nutrion of collagen and its water content. It also aids the secretion of pancreozymine that acts as local anti-inflammatory agent.
6. As claimed in any previous claim. The
Metamorf compounds 561, "2" (561) "3" (561) was found to be acting as:- A buffer and stabiliser within the alkaline reserve of blood.
Influences the majority of enzymatic processes at the cellular and subcellular level, (enzyme activator) dependent on an optimal pH. It has a saponim-like action in the sense of an emulsifier acting on the cell membrane, one of which is the maintenance of the fluidity: coagulability of blood.
It is a detoxificating agent meadiating a correct performance of the intermediary metabolism of the liver, particularly that of the mevalonic acid.
Influences the degradation of pyrovate into acetyl-co enzyme-A and the initiation of the citricacid-cycle (Kreks cycle). It mediates the secretion of mucin by its local action on the mucosa of the upper part of the gastro-intestinal tract.
Bradykinin triggers off the pain. The compound neutralizes this and/or influences its intensity, and shows it analgestic properties. Mediates the reversibility of the early demyelination and improves or slows down the process in later stages of the multiple sclerosis. The formulation is such that it is impossible to overdose, and there are no known side effects. Taken orally undiluted before meals. No liquids for 30 minutes after taken.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08123639A GB2111384A (en) | 1981-08-03 | 1981-08-03 | Improvement in preventative and curative medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08123639A GB2111384A (en) | 1981-08-03 | 1981-08-03 | Improvement in preventative and curative medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB2111384A true GB2111384A (en) | 1983-07-06 |
Family
ID=10523647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB08123639A Withdrawn GB2111384A (en) | 1981-08-03 | 1981-08-03 | Improvement in preventative and curative medicine |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2111384A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2222769A (en) * | 1988-09-16 | 1990-03-21 | Toyotama Perfumery | Antitumour agent |
| EP0727987A4 (en) * | 1992-01-31 | 1998-03-11 | Scripps Research Inst | Inhibition of respiratory burst using posttranslational modification inhibitors |
| EP1213027A3 (en) * | 2000-12-11 | 2003-01-15 | Kyowa Hakko Kogyo Co., Ltd. | Liver function protecting or improving agent |
| WO2007098680A1 (en) * | 2006-02-28 | 2007-09-07 | Gang Shu | The uses of d-limonene, plant or valatile oil thereof containing d-limonene in manufacturing medicaments for preventing and treating diabetes |
| WO2009053793A3 (en) * | 2007-08-27 | 2009-07-09 | Gang Shu | Use of volatile oil from plants in preparing medicaments for preventing and treating diabetes |
-
1981
- 1981-08-03 GB GB08123639A patent/GB2111384A/en not_active Withdrawn
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2222769A (en) * | 1988-09-16 | 1990-03-21 | Toyotama Perfumery | Antitumour agent |
| DE3922666A1 (en) * | 1988-09-16 | 1990-03-22 | Toyotama Perfumery Co | ANTITUMOR MEDIUM |
| FR2636533A1 (en) * | 1988-09-16 | 1990-03-23 | Toyotama Perfumery | PHARMACEUTICAL COMPOSITION AND ANTITUMOR AGENT BASED ON LIMONOIDES CITRUS |
| GB2222769B (en) * | 1988-09-16 | 1992-01-22 | Toyotama Perfumery | Antitumor agent |
| EP0727987A4 (en) * | 1992-01-31 | 1998-03-11 | Scripps Research Inst | Inhibition of respiratory burst using posttranslational modification inhibitors |
| EP1213027A3 (en) * | 2000-12-11 | 2003-01-15 | Kyowa Hakko Kogyo Co., Ltd. | Liver function protecting or improving agent |
| WO2007098680A1 (en) * | 2006-02-28 | 2007-09-07 | Gang Shu | The uses of d-limonene, plant or valatile oil thereof containing d-limonene in manufacturing medicaments for preventing and treating diabetes |
| WO2009053793A3 (en) * | 2007-08-27 | 2009-07-09 | Gang Shu | Use of volatile oil from plants in preparing medicaments for preventing and treating diabetes |
| US8337907B2 (en) | 2007-08-27 | 2012-12-25 | Gang Shu | Use of volatile oil from plants in preparing medicaments for preventing and treating diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bever | Oral hypoglycaemic plants in West Africa | |
| EP0022046A1 (en) | Drug composition based on plants and process for its preparation | |
| RU2599826C2 (en) | Biologically active supplement | |
| RU2162702C1 (en) | Preparation of restorative and tonic action | |
| Saad | Integrating traditional Greco‐Arab and Islamic diet and herbal medicines in research and clinical practice | |
| CN101518354A (en) | Hypertension relieving vinegar beverage and preparation method thereof | |
| CN104560576A (en) | Lepidium meyenii walp health wine and preparation method thereof | |
| GB2111384A (en) | Improvement in preventative and curative medicine | |
| KR102560440B1 (en) | Health functional food composition for improving joint health and manufacturing method thereof | |
| KR20120121468A (en) | anhydrous lactobacillus fermentation health function food composition with sex funstion improvements effects | |
| EP2132994B1 (en) | Fermentation of solutions containing pomegranate juice with saccharomyces boulardii and lactobacilli, resulting fermented products and application thereof | |
| EP1637149A1 (en) | Dietary supplement composition for the man | |
| Khan et al. | Nutritional importance and pharmacological activity of Mangifera indica | |
| CN1084167C (en) | Ginkgo vinegar drink | |
| LU501504B1 (en) | POWDERED FOOD SUPPLEMENT FOR MAKING A BEVERAGE | |
| WO2003080062A1 (en) | Composition comprising vitamin b9, vitamin b6, lipoic acid and plant extracts for treating circulatory disorders | |
| KR20020075989A (en) | Manufacturing method of a ferment drink using Sambakcho and Eosungcho | |
| KR20030032758A (en) | The manufacture of add propolis to function solt | |
| KR20110090217A (en) | Lactobacillus anhydrous fermentation health functional food composition having an effect on improving sexual function and a method of manufacturing the same | |
| WO1989006966A1 (en) | Herbal tea composition and process for producing it | |
| RU2228761C1 (en) | Agent declining toxic effect of alcohol and method for its preparing | |
| Tsai et al. | α-Glucosidase Inhibitory Activity and Antioxidant Activity of Pomelo (Citrus grandis) Peel, Albedo, and Flavedo Extracts. | |
| KR102466436B1 (en) | beverage composition | |
| RU2122813C1 (en) | Alcohol-free beverage "fregat" | |
| Singh et al. | The Golden Superfruit: Unveiling the Nutritional Riches and Multifaceted Health Benefits of Seabuckthorn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |